Under a five-year agreement with the drug and medical device industry, the FDA will receives approximately $6.4 billion in user fees to fund reviews of drugs and medical devices.
Those fees, however, cannot be used until the FDA receives federal funding, which is at stake as $1.2 trillion of federal budget cuts set in through 2012. Under the Budget Control Act, the FDA could lose as much as $200 million for fiscal year 2013. The funding could affect not only product reviews but also jobs at the federal agency.
Lawmakers are currently at a stalemate on whether to comply with the funding cuts required under the Budget Control Act.
More Articles on the FDA:
InVivo Therapeutics Names Interim Chief Science Officer
EOS, IMDS Partner for Medical Devices
NeuroTherm Appoints Gregory Cash as New President & CEO
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
